

## Andrew T. Serafini Ph.D.

### Partner

1420 Fifth Avenue  
 Suite 3700 , Seattle , WA USA 98101  
 t 206.626.7769 | f 206.374.2918  
 atserafini@kilpatricktownsend.com

#### Services

Adversarial Patent Prosecution<sup>SM</sup>  
 Asset Creation - Prosecution &  
 Counseling  
 Biologics & Pharmaceutical Patent  
 Litigation  
 Intellectual Property  
 Licensing, Transactions &  
 Monetization  
 Market Protection - Opinions &  
 Dispute Avoidance  
 Patent Litigation  
 Patents  
 Post-Grant Proceedings  
 Trade Secrets

#### Industries

Apparel, Accessories & Luxury  
 Goods  
 Chemicals  
 Consumer Goods  
 Electronics & Computer  
 Technology  
 Health & Life Sciences  
 Medical & Surgical Devices  
 Retail & Consumer Goods  
 Technology



Andrew Serafini is a registered patent lawyer who focuses his practice on strategic and comprehensive intellectual property counseling and management to biotechnology, biopharmaceutical and other life sciences clients. Dr. Serafini was recognized as a top patent practitioner in 2019 and the four years immediately preceding by *IAM Patent 1000 – The World's Leading Patent Practitioners*. He was listed in the 2018 and 2019 editions of *Chambers USA: America's Leading Lawyers for Business* in the area of Intellectual Property and *Chambers USA* also ranked Dr. Serafini as a "Recognized Practitioner" in its 2018 edition.

As a scientist, Dr. Serafini enjoys the pursuit of innovation in his scientific research – as a lawyer, he uses his scientific background to strengthen his clients' positions. He assists his clients in obtaining, protecting, and enforcing their intellectual property rights, especially in the areas of immunology, molecular biology, chemistry, antibody engineering and therapeutics, vaccines, stem cell technologies, molecular genetics, genomics, proteomics and protein chemistry, pharmaceuticals, medical therapeutics, nanotechnology, clean energy,

medical diagnostics, and personalized medicine.

In over twenty years of practice, Dr. Serafini has focused on strategic and comprehensive intellectual property counseling and management for biotechnology, biopharmaceutical, and other diverse life sciences clients. He fully engages with his clients, so he knows not only his clients' wants and needs, but also how to best realize his clients' goals given the pressures of business, the innovations of science, and the connections of the global community.

Dr. Serafini's practice includes preparing and prosecuting U.S. and international patents; performing due diligence and freedom to operate analyses associated with mergers and acquisitions, venture capital and other private and public financings; drafting opinions on patentability, non-infringement and patent validity; product development counseling; supporting patent infringement litigation, post grant proceedings, and International Trade Commission investigations.

Dr. Serafini guided the development of the intellectual property estate for Medarex's ipilimumab (Yervoy™), a first-in-class monoclonal antibody and checkpoint inhibitor directed at CTLA-4, a protein receptor and key target in cancer immunotherapy.

Dr. Serafini is also an Adjunct Professor of Law at the University of Washington (UW) School of Law teaching advanced courses in intellectual property. He also advises and mentors law students participating in independent study programs and law clinics, including the UW School of Law Entrepreneurial Law Clinic.

Dr. Serafini is a Director on the Life Science Washington (LSW) Board. LSW, formerly the Washington Biotechnology & Biomedical Association, is an independent, non-profit trade association serving the life sciences industry in the state of Washington. LSW members include organizations engaged in, or supportive of, the research, development and commercialization of life science technologies. Dr. Serafini was recognized as the Volunteer of the Year at the 2013 Governor's Life Science Summit and WBBA Annual Meeting.

Dr. Serafini is a Director on the Antibody Society of Korea Board ("ASK"; Republic of Korea).

He is also President of the Board of Directors for the Washington Rush (WA Rush) Youth Soccer Club. WA Rush is committed to the development of healthy youth through the game of soccer.

## **Education**

University of California, Hastings College of the Law, J.D. (1998)

Stanford University School of Medicine, Ph.D., Immunology (1994)

Case Institute of Technology of Case Western Reserve University, B.S., Biochemistry (1986) *with honors*



## **Admissions**

Washington (2003)

## **Court Admissions**

U.S. Patent and Trademark Office (1997)

U.S. Court of Appeals for the Ninth Circuit

U.S. District Court for the Western District of Washington

U.S. Court of Appeals for the Federal Circuit

## **Professional & Community Activities**

Life Science Washington, Board of Directors

Washington Rush Youth Soccer Club, Board of Directors, President

American Bar Association, Member

Federal Circuit Bar Association, Member

Washington State Bar Association, Member

American Intellectual Property Association, Member

Washington State Patent Law Association, Member

Licensing Executive Society (U.S.A. & Canada) Inc., Member

Association of University Technology Managers, Member

American Association of the Advancement of Science, Member

## **Insights**

### **Events**

Legal Issues and Recent Developments: Licensing, Patents and Trade Secrets

July 25, 2019

### **Events**

Protecting Trade Secrets

July 23, 2019

### **News Releases**

Kilpatrick Townsend Receives High Rankings in 2019 IAM Patent 1000

July 11, 2019



### Events

CAR T-cells: History, Function, Evolution and More

July 6, 2019

### News Releases

Kilpatrick Townsend Achieves Top-Tier Recognition from Chambers USA 2019

May 2, 2019

### Events

How Should Start-ups Protect Innovation?

February 15, 2019

### Events

Intellectual Property Strategies for Therapeutic Antibodies

October 22, 2018

### Events

Protecting Innovation: Therapeutic Antibodies

July 6, 2018

### News Releases

Kilpatrick Townsend Recognized in 2018 IAM Patent 1000

July 2, 2018

### Events

Patents and Trade Secrets: Protecting Innovation

June 28, 2018

### News Releases

Kilpatrick Townsend Achieves Recognition From Chambers USA 2018

May 11, 2018

### Events

Global Intellectual Property Portfolio Management & Related Strategy Considerations

July 21, 2017



### Events

Cybersecurity Issues in the Health Care Industry

July 10, 2017

### Events

Legal Issues Surrounding Research and Commercial Use of Human Biological Materials and Their Derivatives

June 30, 2017

### News Releases

Kilpatrick Townsend Receives High Rankings in 2017 IAM Patent 1000

June 8, 2017

### Events

Patent Eligible Subject Matter: In the Context of Biomarker Innovations

May 15, 2017

### Events

New Horizons in Therapeutics and Interventions

May 3, 2017

### Events

Intellectual Property Protection & Commercialization: Putting Patents to Work

August 24, 2016

### Events

Patent Eligible Subject Matter: Biomarkers, Diagnostics and Bioinformatics

August 23, 2016

### Events

New Guidelines on Subject Matter Eligibility for Patenting

August 1, 2016

### Events

Global Intellectual Property Portfolio Management & Related Strategy Considerations

July 14, 2016



### Alerts

“Patents 4 Patients”: A New Cancer Immunotherapy “Fast Track” for U.S. Patent Applicants

July 6, 2016

### Events

Intellectual Property Protection

July 1, 2016

### News Releases

Kilpatrick Townsend Attorneys Named to 2016 IAM Patent 1000

June 2, 2016

### Events

Forum on Patentability of Biomarkers and Diagnostics

May 23, 2016

### Events

Patentable Subject Matter in Biotechnology: Legal, Social & Ethical Considerations

March 8, 2016

### Events

Patentability and Patent Extension of New Use and New Dosage Regimen for Existing Drugs

December 4, 2015

### Events

Antibodies and Other Patentable Subject Matter in the US: After Myriad and the Revised US Patent Office Interim Guidance

November 6, 2015

### Events

Antibodies: After Myriad and the Revised US Patent Office Interim Guidance

October 29, 2015

### Events

Intellectual Property Protection and Commercialization

October 5, 2015



### Events

Life Science Innovation Northwest

June 30, 2015

### In The News

Kilpatrick Townsend's Media Report June 19-25, 2015

June 26, 2015

### News Releases

Twenty-Two Kilpatrick Townsend Attorneys Named to 2015 IAM Patent 1000

June 18, 2015

### In The News

Kilpatrick Townsend's Media Report May 15-21, 2015

May 22, 2015

### Events

Research & Development: Any Patentable Subject Matter in the US after the Revised Myriad Interim Guidance

May 7, 2015

### Events

Technology and Innovation Management Program

April 29, 2015

### In The News

Kilpatrick Townsend's Media Report April 17-23, 2015

April 24, 2015

### Events

Patent Pools: Navigating a Course for Access to Biotechnology Innovations

April 21, 2015

### Events

Inside an Acquisition

February 25, 2015



[News Releases](#)

Kilpatrick Townsends Andrew Serafini Appointed to the Board of Directors of Washington Biotechnology & Biomedical Association

February 2, 2015